Pfizer Inc. (NYSE: PFE) today announced positive results from Cohort 3, a separate randomized cohort of the pivotal ...
Colorectal cancer is the third most common cancer globally, with approximately 1.8 million people diagnosed in 2022 ...
US pharma giant Pfizer on Saturday announced positive results from Cohort 3, a separate randomized cohort of the pivotal ...
Pfizer Inc. (NYSE: PFE) today announced positive results from Cohort 3, a separate randomized cohort of the pivotal BREAKWATER trial, evaluating ...
The BREAKWATER trial showed improved response rates and survival with Braftovi, Erbitux, and chemotherapy in BRAF V600E-mutated metastatic colorectal cancer. FDA approval in December 2024 highlights ...
HER2-Selective Tyrosine Kinase Inhibitor, Zongertinib (BI 1810631), in Patients With Advanced/Metastatic Solid Tumors With HER2 Alterations: A Phase Ia Dose-Escalation Study Supported by the NIH/NCI ...
Hosted on MSN
BRAF gene mutation leads to different therapeutic responses in melanoma and colorectal cancer
A review article led by researchers from the B·ARGO group at the Germans Trias i Pujol Research Institute (IGTP) and from the Medical Oncology Department of the Catalan Institute of Oncology (ICO) in ...
View all available purchase options and get full access to this article. The following represents disclosure information provided by authors of this manuscript. All relationships are considered ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback